INFLUX
NSEPrice History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Trend
Mixed MA signals — sideways/transition
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Influx Healthtech Limited | ₹289.00 | -0.65% | 22.0 | ₹669 Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for INFLUX
View All
Aukera raises ₹90 crore debt funding to expand lab-grown diamond jewellery business
In a significant move, lab-grown diamond brand Aukera raised ₹90 crore in debt financing, spearheaded by Alteria Capital. This influx of capital is earmarked for enhancing retail presence and advancing product innovation. Aukera's strategy includes opening additional outlets in both familiar and new cities, as the company targets the upscale segment of the booming market, ensuring a robust balance sheet for upcoming industry shifts.
Peak XV nets 12 fold gain on K12 Techno after Vitruvian infuses ₹1,159 crore
Peak XV Partners has achieved a remarkable 12-fold return on its investment after a substantial ₹1,159 crore influx from Vitruvian Partners into K12 Techno Services. This deal catapults K12's valuation and highlights its rapid growth in India's booming education market.
Akasa Air plans to operate flights under UDAN scheme, says CEO Vinay Dube
Akasa Air is set to join the UDAN regional connectivity scheme, with CEO Vinay Dube confirming a steady influx of Boeing 737 MAX aircraft. The airline plans significant capacity growth, aiming for 30% this fiscal year and 30-40% over the next 4-5 years. Despite industry-wide delivery challenges, Akasa Air's fleet expansion remains on track, with a strategic focus on a single aircraft type and class.